The acquisition became effective on March 30, 2026 and includes the Wokadine® brand, which is ranked No. 2 in the Povidone Iodine market in India.
With the transaction, Corona Remedies will enter the ₹648 crore Povidone Iodine market, expanding its footprint in the segment and enhancing its offering across targeted specialties.
The company said Wokadine® has a legacy of 46 years of trust and protection and holds strong potential for accelerated growth under Corona Remedies’ stewardship.
The brand comprises 14 SKUs with multiple applications and is widely used by clinicians, including surgeons, ENT specialists, general physicians and gynaecologists.
Corona Remedies said integrating Wokadine® into its portfolio will help deepen its reach across targeted specialties and improve accessibility for patients.
The company added that its sales and marketing team, supported by an extensive distribution network, will work to ensure the newly acquired portfolio reaches patients across metro, semi-metro, urban, semi-urban and rural markets.
According to the company, the acquisition will be fully funded through internal accruals and available cash.
Commenting on the development, Tejas Kothari, Vice President – Corporate Strategy & Business Development at Corona Remedies, said the company continues to evaluate both organic and inorganic growth opportunities to strengthen its brands and expand market penetration.
He added that the acquisition is expected to enhance the company’s existing product portfolio and support growth by leveraging strong relationships with healthcare professionals and its pan-India distribution network.
Also read: Corona Remedies turns acquired Myoril brand into a growth engine ahead of its ₹655-crore IPO
On the stock market, shares of Corona Remedies fell 1.99% to ₹1,550 on the NSE.
